J. Bartlett

发表

Modification and labeling of AAV vector particles.

M. Hallek, H. Büning, C. Bolyard, 2011, Methods in molecular biology.

Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy

R. Samulski, J. Bartlett, 1998, Nature Medicine.

αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection

R. Samulski, J. Bartlett, C. Summerford, 1999, Nature Medicine.

Genetically Expressed Monodisperse α Helical Polypeptides

R. Samulski, E. Samulski, J. Bartlett, 1996 .

Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.

A. Ting, J. Bartlett, Irwin Chen, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Preclinical safety and efficacy of an anti–HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

K. Cornetta, I. Chen, J. Bartlett, 2014, Molecular therapy. Methods & clinical development.

CCR5 as a Natural and Modulated Target for Inhibition of HIV

J. Bartlett, G. Hütter, G. Symonds, 2013, Viruses.

Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS

Shiu-Lok Hu, H. Kiem, J. Bartlett, 2016, Molecular therapy. Methods & clinical development.

Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.

H. Kiem, J. Bartlett, G. Symonds, 2016, AIDS patient care and STDs.

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

R. Samulski, J. Bartlett, C. Summerford, 1999, Nature medicine.

Gene delivery to the vasculature mediated by low‐titre adeno‐associated virus serotypes 1 and 5

F. Barry, S. Conroy, Z. Katušić, 2008, The journal of gene medicine.

Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma.

A. Hemminki, J. Bartlett, W. Shi, 2006, Gynecologic oncology.

Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors

N. Wong, J. Bartlett, Qiang Liu, 2002, Journal of Virology.

Adeno-associated virus 2 co-receptors?-second reply

R. Samulski, J. Bartlett, Candance Summerford, 1999, Nature Medicine.

Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.

J. Bartlett, A. Sasser, M. Stachler, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene therapy: Recombinant adeno-associated virus vectors

J. Bartlett, J. Smith-Arica, 2001, Current cardiology reports.

Osteogenic gene regulation and relative acceleration of healing by adenoviral‐mediated transfer of human BMP‐2 or ‐6 in equine osteotomy and ostectomy models

J. Bartlett, J. Mattoon, A. Litsky, 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Genetics and Biology of Adeno-Associated Virus

R. Samulski, J. Bartlett, 1995 .

Inflammation and Immune Response of Intra-Articular Serotype 2 Adeno-Associated Virus or Adenovirus Vectors in a Large Animal Model

J. Bartlett, Akikazu Ishihara, A. Bertone, 2012, Arthritis.

Detectable reporter gene expression following transduction of adenovirus and adeno‐associated virus serotype 2 vectors within full‐thickness osteoarthritic and unaffected canine cartilage in vitro and unaffected guinea pig cartilage in vivo

G. Nuovo, J. Bartlett, J. Dyce, 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Evaluation of permissiveness and cytotoxic effects in equine chondrocytes, synovial cells, and stem cells in response to infection with adenovirus 5 vectors for gene delivery.

J. Bartlett, Akikazu Ishihara, A. Bertone, 2006, American journal of veterinary research.

Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.

B. Byrne, S. Jacobson, K. Cornetta, 2013, Human gene therapy.

Adeno-associated virus vectors for human gene therapy

R. Samulski, J. Bartlett, 2020, Gene Therapy.

Factors Influencing Adeno-Associated Virus-Mediated Gene Transfer to Human Cystic Fibrosis Airway Epithelial Cells: Comparison with Adenovirus Vectors

R. Samulski, S. Teramoto, J. Bartlett, 1998, Journal of Virology.

Estrogen plays a critical role in AAV2-mediated gene transfer in ovarian cancer

J. Bartlett, W. Shi, 2008, Acta Pharmacologica Sinica.

Mechanisms of AAV transduction in glaucoma‐associated human trabecular meshwork cells

V. Choi, R. Samulski, J. Bartlett, 2006, The journal of gene medicine.

Selective and rapid uptake of adeno-associated virus type 2 in brain.

R. Samulski, J. Bartlett, R. Samulski, 1998, Human gene therapy.

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

I. Chen, J. Bartlett, D. An, 2015, Molecular therapy. Nucleic acids.

Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors

N. Wong, V. Holers, J. Bartlett, 2008, Journal of Virology.

Molecular Characterization of Adeno-Associated Viruses Infecting Children

Philip R. Johnson, M. Connell, Chun-Liang Chen, 2005, Journal of Virology.

Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors

R. Samulski, J. Bartlett, R. Wilcher, 2000, Journal of Virology.

Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery.

William C. Ray, N. Boulis, J. Bartlett, 2015, Neurosurgery.

RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.

J. Bartlett, W. Shi, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism.

J. Bartlett, W. Shi, Guangguang Fang, 2006, Human gene therapy.

Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.

J. Bartlett, W. Shi, G. S. Arnold, 2001, Human gene therapy.

Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody

R. Samulski, J. Kleinschmidt, J. Bartlett, 1999, Nature Biotechnology.

Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells

J. Bartlett, M. Stachler, 2006, Gene Therapy.

Mesenchymal stem cell-mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model.

Alisha Diggs, J. Bartlett, S. Weisbrode, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene-eluting stents: comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall in vivo.

Timothy O'Brien, Kieran Daly, James Crowley, 2006, Human gene therapy.

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

I. Chen, J. Bartlett, D. An, 2015, Molecular therapy. Nucleic acids.

Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.

A. Ting, J. Bartlett, Irwin Chen, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.